Research output per year
Research output per year
Personal profile
Biography
Dr. Natasha Anstee completed her PhD in 2015 at The Walter and Eliza Hall Institute of Medical Research where she was supervised by Prof. Suzanne Cory. During her PhD, Dr. Anstee investigated the consequences of overexpression of the prosurvial protein MCL-1 for haemopoiesis, autoimmunity and for the development and treatment of MLL-AF9-induced AML.
From 2017-2019 Dr. Anstee worked as a Postdoctoral Reseach Fellow at the German Cancer Research Centre (DKFZ) and Heidelberg Institute of Stem Cell Technology and Experimental Medicine (HI-STEM) in the laboratory of Dr. Michael Milsom. Her research was focused on reassessing the concept of haempoietic stem cell self-renewal based on single cell tranplantation outcomes.
In 2020 she joined the Leukemia Research Group, led by A/Prof. Andrew Wei at the Austrlian Centre for Blood Diseases (Monash University), based at The Alfred Hospital. She is in charge of the correlative studies emerging from AML clinical trials led by A/Prof. Wei, with a major focus on tracking MRD using NGS assays as well investigating clonal evolution through single cell technologies.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Research Scientist, Alfred Hospital
Research area keywords
- Stem cells
- Leukaemia
- Clonal evolution
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Tiong, I. S., Hiwase, D. K., Abro, E., Bajel, A., Palfreyman, E., Beligaswatte, A., Reynolds, J., Anstee, N., Nguyen, T., Loo, S., Chua, C. C., Ashby, M., Wiltshire, K. M., Fleming, S., Fong, C. Y., Teh, T. C., Blombery, P., Dillon, R., Ivey, A. & Wei, A. H., 20 Jun 2024, In: Journal of Clinical Oncology. 42, 18, p. 2161-2173 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access14 Citations (Scopus) -
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
Moujalled, D. M., Brown, F. C., Chua, C. C., Dengler, M. A., Pomilio, G., Anstee, N. S., Litalien, V., Thompson, E., Morley, T., MacRaild, S., Tiong, I. S., Morris, R., Dun, K., Zordan, A., Shah, J., Banquet, S., Halilovic, E., Morris, E., Herold, M. J. & Lessene, G. & 5 others, , 9 Feb 2023, In: Blood. 141, 6, p. 634–644 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access51 Citations (Scopus) -
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia
Sabatier, M., Birsen, R., Lauture, L., Mouche, S., Angelino, P., Dehairs, J., Goupille, L., Boussaid, I., Heiblig, M., Boet, E., Sahal, A., Saland, E., Santos, J. C., Armengol, M., Fernández-Serrano, M., Farge, T., Cognet, G., Simonetta, F., Pignon, C. & Graffeuil, A. & 37 others, , 7 Jul 2023, In: Cancer Discovery. 13, 7, p. 1720-1747 28 p.Research output: Contribution to journal › Article › Research › peer-review
44 Citations (Scopus) -
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
Loo, S., Roberts, A. W., Anstee, N. S., Kennedy, G. A., He, S., Schwarer, A. P., Enjeti, A. K., D'Rozario, J., Marlton, P., Bilmon, I. A., Taper, J., Cull, G., Tiley, C., Verner, E., Hahn, U., Hiwase, D. K., Iland, H. J., Murphy, N., Ramanathan, S. & Reynolds, J. & 17 others, , 7 Dec 2023, In: Blood. 142, 23, p. 1960-1971 12 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access15 Citations (Scopus) -
ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
Wei, A. H., Iland, H. J., Reynolds, J., Loo, S., Chua, C. C., Westerman, D. A., Tiong, I. S., Ivey, A., Blombery, P., Anstee, N. S., Koldej, R., Curtis, D. J., Kipp, D. A., Ritchie, D. S., Ross, D. M., Souza, A., Collins, J., Bajel, A., Grove, C. S. & Marlton, P. & 7 others, , 15 Nov 2022, In: Blood. 140, Suppl 1, p. 3341-3343 3 p.Research output: Contribution to journal › Meeting Abstract › peer-review